NASDAQ:CMRX Chimerix Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Chimerix Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.85 +0.31 (+12.20 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$2.48Now: $2.85▼$2.8950-Day Range$2.30MA: $2.82▼$3.4152-Week Range$1.19Now: $2.85▼$3.88Volume1.05 million shsAverage Volume666,259 shsMarket Capitalization$177.27 millionP/E RatioN/ADividend YieldN/ABeta1.83 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside for the treatment of norovirus; and CMX157, a nucleoside analog for the treatment of HIV and hepatitis B virus infection. The company has license agreements with ContraVir Pharmaceuticals for the development and commercialization of CMX157 for various antiviral indications; and Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingChimerix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Chimerix has a forecasted upside of 145.6% from its current price of $2.85.Amount of Analyst CoverageChimerix has only been the subject of 1 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesChimerix has received 353 “outperform” votes. (Add your “outperform” vote.)Underperform VotesChimerix has received 376 “underperform” votes. (Add your “underperform” vote.)Community SentimentChimerix has received 51.58% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Chimerix and other stocks. Vote “Outperform” if you believe CMRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CMRX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldChimerix does not currently pay a dividend.Dividend GrowthChimerix does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Chimerix insiders have sold 30.85% more of their company's stock than they have bought. Specifically, they have bought $10,220.00 in company stock and sold $13,373.00 in company stock.Percentage Held by InsidersOnly 9.00% of the stock of Chimerix is held by insiders.Percentage Held by Institutions45.88% of the stock of Chimerix is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Chimerix are expected to grow in the coming year, from ($0.67) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chimerix is -1.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Chimerix is -1.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChimerix has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.51 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CMRX Previous Symbol CUSIPN/A CIK1117480 Webwww.chimerix.com Phone919-806-1074Debt Debt-to-Equity RatioN/A Current Ratio15.86 Quick Ratio15.86Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$12.52 million Price / Sales14.16 Cash FlowN/A Price / Cash FlowN/A Book Value$1.79 per share Price / Book1.59Profitability EPS (Most Recent Fiscal Year)($0.86) Net Income$-112,580,000.00 Net Margins-859.64% Return on Equity-31.42% Return on Assets-28.63%Miscellaneous Employees82 Outstanding Shares62,200,000Market Cap$177.27 million Next Earnings Date11/3/2020 (Estimated) OptionableOptionable $2.85 +0.31 (+12.20 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CMRX News and Ratings via Email Sign-up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter. Chimerix (NASDAQ:CMRX) Frequently Asked Questions How has Chimerix's stock price been impacted by Coronavirus (COVID-19)? Chimerix's stock was trading at $1.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CMRX shares have increased by 97.9% and is now trading at $2.85. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Chimerix? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Chimerix. When is Chimerix's next earnings date? Chimerix is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Chimerix. How were Chimerix's earnings last quarter? Chimerix Inc (NASDAQ:CMRX) posted its quarterly earnings data on Monday, August, 10th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.17) by $0.01. The biopharmaceutical company had revenue of $1.40 million for the quarter, compared to analyst estimates of $1.17 million. Chimerix had a negative return on equity of 31.42% and a negative net margin of 859.64%. View Chimerix's earnings history. What price target have analysts set for CMRX? 1 equities research analysts have issued 1 year price objectives for Chimerix's stock. Their forecasts range from $7.00 to $7.00. On average, they expect Chimerix's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 145.6% from the stock's current price. View analysts' price targets for Chimerix. Who are some of Chimerix's key competitors? Some companies that are related to Chimerix include Collegium Pharmaceutical (COLL), Emisphere Technologies (EMIS), DiaMedica Therapeutics (DMCAF), Cara Therapeutics (CARA), Omeros (OMER), Northwest Biotherapeutics (NWBO), Endo International (ENDP), Syndax Pharmaceuticals (SNDX), AC Immune (ACIU), Aprea Therapeutics (APRE), Dynavax Technologies (DVAX), ORIC Pharmaceuticals (ORIC), Molecular Templates (MTEM), Clovis Oncology (CLVS) and XBiotech (XBIT). View all competitors. What other stocks do shareholders of Chimerix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Chimerix investors own include Melinta Therapeutics (MLNT), Immunomedics (IMMU), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Opko Health (OPK), Pfizer (PFE) and SLS International (SLS). Who are Chimerix's key executives? Chimerix's management team includes the following people: Mr. Timothy W. Trost, Sr. VP, CFO & Corp. Sec. (Age 61)Dr. William Garrett Nichols M.D., MS, Chief Medical Officer (Age 50)Mr. Michael A. Sherman, CEO & Pres (Age 53)Dr. Roy W. Ware Ph.D., MBA, Chief Manufacturing & Technology OfficerDr. Randall Lanier Ph.D., Chief Science Officer What is Chimerix's stock symbol? Chimerix trades on the NASDAQ under the ticker symbol "CMRX." Who are Chimerix's major shareholders? Chimerix's stock is owned by a number of retail and institutional investors. Top institutional investors include Opaleye Management Inc. (3.38%), FMR LLC (1.31%), FMR LLC (1.31%), Two Sigma Advisers LP (1.29%), Point72 Asset Management L.P. (1.01%) and Jacobs Levy Equity Management Inc. (0.78%). Company insiders that own Chimerix stock include Fred A Middleton, Garrett Nichols, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer. View institutional ownership trends for Chimerix. Which institutional investors are selling Chimerix stock? CMRX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, FMR LLC, UBS Group AG, Point72 Asset Management L.P., Nuveen Asset Management LLC, Goldman Sachs Group Inc., RBF Capital LLC, and Man Group plc. Company insiders that have sold Chimerix company stock in the last year include Garrett Nichols, and Martha J Demski. View insider buying and selling activity for Chimerix. Which institutional investors are buying Chimerix stock? CMRX stock was purchased by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Jacobs Levy Equity Management Inc., Worth Venture Partners LLC, Two Sigma Advisers LP, Public Employees Retirement System of Ohio, Russell Investments Group Ltd., Jane Street Group LLC, and Vanguard Capital Wealth Advisors. Company insiders that have bought Chimerix stock in the last two years include Fred A Middleton, Martha J Demski, Michael A Sherman, Michael T Andriole, and Robert J Meyer. View insider buying and selling activity for Chimerix. How do I buy shares of Chimerix? Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Chimerix's stock price today? One share of CMRX stock can currently be purchased for approximately $2.85. How big of a company is Chimerix? Chimerix has a market capitalization of $177.27 million and generates $12.52 million in revenue each year. The biopharmaceutical company earns $-112,580,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Chimerix employs 82 workers across the globe. What is Chimerix's official website? The official website for Chimerix is www.chimerix.com. How can I contact Chimerix? Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected] This page was last updated on 9/19/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
